PCR与分子诊断:临床实验室中的生物技术整合
本文综述PCR技术从传统扩增到qPCR、dPCR、RT-PCR及多重PCR等先进平台的发展,并讨论其与NGS、CRISPR诊断系统、微阵列及表观遗传分析等技术的整合。文章聚焦EGFR、KRAS、BRAF、BCR-ABL1、ctDNA及甲基化SEPT9等临床相关生物标志物,涵盖肿瘤、感染性疾病、抗菌药物耐药监测、遗传病检测、微生物群落研究及MRD监测等应用,并涉及液体活检、即时分子检测及AI辅助多组学数据分析等趋势。
要点
- PCR仍是当前最通用且具临床适用性的分子技术。
- 先进PCR平台支持核酸准确定量及高通量分析。
- PCR与NGS、CRISPR、微阵列等整合可拓展疾病评估视野。
核心结论
- PCR技术从传统扩增发展至qPCR、dPCR、RT-PCR和多重PCR等先进平台,并与NGS、CRISPR诊断系统、微阵列及表观遗传分析整合,拓展了疾病状态评估能力。
- 尽管存在成本、标准化协议、技术人员培训及大数据管理等挑战,技术进步正使这些方法更可及于临床医生和患者。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 先进PCR平台有助于核酸的准确检测与定量,并支持高通量分析。
- PCR与NGS、CRISPR诊断系统、微阵列及表观遗传分析整合可提供更全面的疾病状态视图。
- EGFR、KRAS、BRAF、BCR-ABL1、ctDNA及甲基化SEPT9等标志物在肿瘤早期诊断、预后、治疗监测及精准医学中具有价值。
- PCR技术还应用于感染性疾病诊断、抗菌药物耐药追踪、遗传性疾病检测、微生物群落研究及MRD监测。
临床怎么用
- 临床实验室可依据需求选择传统PCR或qPCR、dPCR、RT-PCR、多重PCR等平台进行核酸定性与定量检测。
- 可将PCR与NGS、CRISPR诊断、微阵列等技术整合,用于肿瘤标志物检测、感染病原鉴定及耐药监测等场景。
- 液体活检与即时分子检测平台为临床提供更便捷的分子诊断途径。
局限性
- 技术开发成本较高。
- 各技术类型缺乏标准化协议。
- 需要熟练技术人员进行开发与验证。
- 使用过程中产生大量数据,管理存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A new generation of molecular tests has revolutionized laboratory medicine through allowing for quick, sensitive, and precise identification of the pathogen; genetic mutation or alteration; and disease-related bio-markers. Of all the molecular techniques that exist today, PCR is still the most versatile, and clinically applicable technique available. This paper reviews the development of PCR technology from traditional amplification to advanced platforms including qPCR, dPCR, RT-PCR, and multiplex PCR. Each of the advanced platforms reviewed will be examined for their contributions to both the accurate detection, and quantification of nucleic acids along with the ability to perform high throughput analyses. Additionally, this paper also discusses how PCR technology can be integrated with additional technologies such as NGS, CRISPR-based diagnostic systems, microarrays, and epigenetic profiling to provide a larger view of disease states than was previously possible. Specifically, the focus of this paper will include many clinically relevant biomarkers and molecular targets used in cancer research including EGFR, KRAS, BRAF, BCR-ABL1, circulating tumor DNA (ctDNA), and methylated SEPT9. These biomarkers and molecular targets have greatly enhanced early diagnosis, prognostication, treatment monitoring and precision medicine in cancer research and other areas. The use of PCR-based technologies in diagnosing infectious diseases, tracking AMR, detecting heritable disorders, studying microbial communities, and MRD monitoring were also discussed. Further discussion included current trends in integrating multiple omics data types into a single platform using AI assisted data analysis tools. Liquid biopsy technologies and point-of-care molecular test platforms were also discussed. Although there are continuing challenges related to costs associated with developing these technologies, establishing standardized protocols for each technology type developed, having skilled technicians develop and validate these technologies, and managing large amounts of data generated when using these technologies; continued advances are providing greater access to these technologies to clinicians and ultimately patients.
引用
- Saleem MA, Riaz T, Saleem F, et al. PCR and molecular diagnostics: Biotechnologic integration in clinical laboratories. Clin Chim Acta. 2026. PMID: 42586250. doi:10.1016/j.cca.2026.121261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。